Browse DORAS
Browse Theses
Search
Latest Additions
Creative Commons License
Except where otherwise noted, content on this site is licensed for use under a:

Docetaxel uptake and modulation of P-gpmediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines

Collins, Denis (2008) Docetaxel uptake and modulation of P-gpmediated docetaxel efflux by tyrosine kinase inhibitors in human lung carcinoma cell lines. PhD thesis, Dublin City University.

Full text available as:

[img]
Preview
PDF (main paper) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
4Mb
[img]
Preview
PDF (Appendix B legends) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
8Kb
[img]Video (AVI) (A54910microMepirubicinANM.avi)
15Mb
[img]Video (AVI) (A54910microMepirubicin_OP.avi)
794Kb
[img]Video (AVI) (DLKP10microMepirubicinANM.avi)
15Mb
[img]
Preview
Image (TIFF) (DLKPA_2microM_epirubicin_Control_.tif)
796Kb
[img]
Preview
Image (TIFF) (DLKPA_2microM_epirubicin_10_microM_Cyclosporin_A_Zm.tif)
796Kb
[img]
Preview
Image (TIFF) (DLKPA_2microM_epirubicin_10_microM_Cyclosporin_A.tif)
796Kb
[img]
Preview
Image (TIFF) (DLKPA_2microM_epirubicin_100_microM_Verapamil_Zm.tif)
796Kb
[img]
Preview
Image (TIFF) (DLKPA_2microM_epirubicin_100_microM_Verapamil_.tif )
796Kb
[img]Video (AVI) (DLKP_90_min_exposure_to_1_microM_Oregon_green_paclitaxel_3D_ANM.avi)
74Mb
[img]Video (AVI) (DLKP_90_min_exposure_to_1_microM_Oregon_green_paclitaxel_OP.avi)
770Kb
[img]Video (AVI) (DLKP_180_min_exposure_to_1_microM_Oregon_green_paclitaxel_3D_ANM.avi)
74Mb
[img]Video (AVI) (DLKP_180_min_exposure_to_1_microM_Oregon_green_paclitaxel_CS_ANM.avi)
60Mb

Abstract

Treatment with the taxanes, docetaxel and paclitaxel, can result in the emergence of multi-drug resistance (MDR) mediated by P-gp (MDR-1, ABCB1), which is an effective cellular efflux pump for both agents. This thesis was undertaken to examine the contribution of drug transport mechanisms to chemotherapeutic drug resistance, focussing on docetaxel. Sensitive and resistant NSCLC cell lines were used to model docetaxel transport and examine the ability of three tyrosine kinase inhibitors (TKIs), gefitinib, erlotinib and lapatinib, to circumvent resistance to docetaxel, and other chemotherapeutic agents, arising from P-gp over-expression. A HPLC – based method was initially employed to quantify docetaxel levels in cells. The very high taxane levels required rendered this method unreliable for prediction of pharmacologically relevant effects. A more sensitive radiolabel-based technique was then developed to examine lower, pharmacologically achievable concentrations (100-500 nM) of docetaxel. The radiolabel-based assay was then applied to examining docetaxel uptake in the DLKP and A549 NSCLC cell lines and docetaxel accumulation and efflux in the Pgp over-expressing A549-Taxol and DLKP-A cell lines. Passive diffusion is believed to be the mechanism of uptake for docetaxel in most cancer cells due to its lipophilic characteristics. However, evidence was found for an energydependent docetaxel uptake mechanism in DLKP and a non-P-gp energy-dependent efflux mechanism in A549. The contribution of the OATP (organic anion transporting polypeptides) family of transporters to docetaxel uptake in A549 could not be discounted. The existence of transporter-mediated docetaxel uptake in NSCLC cells represents an important new factor in determining the sensitivity of cancer cells to docetaxel. Studies on the TKIs revealed that lapatinib interacted with the ATPase function of P-gp in a manner distinct from gefitinib and erlotinib at clinically achievable concentrations. Lapatinib is most likely a slowly-transported substrate with high affinity for P-gp while erlotinib and gefitinib are most likely transported P-gp substrates. As a result of this, P-gp over-expression may contribute to erlotinib and gefitinib, but not lapatinib, resistance at pharmacological concentrations. Results suggest the three TKIs, particularly lapatinib, have potential clinical utility as MDR modulators capable of augmenting the cytotoxic activity of P-gp substrate chemotherapeutic agents against P-gp positive tumour cells. In addition, each TKI altered EGFR and P-gp protein expression levels.

Item Type:Thesis (PhD)
Date of Award:March 2008
Refereed:No
Supervisor(s):Clynes, Martin and O'Connor, Robert
Subjects:Biological Sciences > Biotechnology
Medical Sciences > Pharmacology
Medical Sciences > Cancer
DCU Faculties and Centres:DCU Faculties and Schools > Faculty of Science and Health > School of Biotechnology
Research Initiatives and Centres > National Institute for Cellular Biotechnology (NICB)
Use License:This item is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 License. View License
ID Code:142
Deposited On:31 Mar 2008 by DORAS Administrator. Last Modified 02 Feb 2009 11:15

Download statistics

Archive Staff Only: edit this record